2007 -2017 Director, Preclinical Drug Development @
2007 -2007 Interim Director, Applied Life Sciences and Toxicology (Site Manager), 2007 @
1999 -2000 Senior Scientist and Toxicologist @
1998 -1999 Clinical Assistant Proffessor, College of Pharmacy (2000-present); Postdoctoral Fellow, 1998-99 @
1997 -1998 Postdoctoral Fellow @
Matthew Reed Education
Texas A&M University
PhD (Pharmacology and Toxicology)
1992-1997
Texas A&M University
Bachelor's degree (Biology, General)
1989-1992
Panola College
General Studies
1988-1989
Matthew Reed Skills
pharmacology and toxicology of inhaled therapeutics and vaccines
Preclinical drug and vaccine research and development programs
chemical, radiological, biological, and nuclear defense/ protection R&D
vaccines
anthrax vaccines and preclinical programs
influenza preclinical programs
infectious disease preclinical programs
pharmacology/toxicology of respiratory, cardiovascular and infectious diseases
inhaled drug development
Toxicology
Pharmacology
Infectious Diseases
Science
Lifesciences
IND
Drug Development
Pharmacokinetics
In Vivo
Clinical Development
Pharmaceutics
Animal Models
In Vitro
Drug Discovery
Pharmaceutical Industry
Life Sciences
Biotechnology
GLP
R&D
Good Laboratory Practice (GLP)
Research and Development (R&D)
Matthew Reed Summary
Matthew Reed, based in New Mexico, United States, is currently a Chief Scientific Officer at Nob Hill Therapeutics. Matthew Reed brings experience from previous roles at Coelus, Lovelace Biomedical and Lovelace Biomedical Research Institute. Matthew Reed holds a 1992 - 1997 PhD in Pharmacology and Toxicology @ Texas A&M University. With a robust skill set that includes pharmacology and toxicology of inhaled therapeutics and vaccines, Preclinical drug and vaccine research and development programs, chemical, radiological, biological, and nuclear defense/ protection R&D, vaccines, anthrax vaccines and preclinical programs and more. Matthew Reed has 2 mobile phone numbers on RocketReach.
Looking for a different Matthew Reed?
Find contact details for 700 million professionals.